{"texts": ["SUCCESSFUL\nPatient reports headache \n\u00b7 \nIV hydration - Rehydrate 20-30 minutes \n\u00b7 \nConsider re-dosing medications on page 2 (See Appendix)\n\u00b7 \nConsider other adjunctive options (See Appendix)\n\u00b7 \nED patients: consider Observation Unit\n\u00b7 \nConsider Neurology consult if patient has:\no \nFrequent ED visits (> 2 times/month)\no \nAtypical pain\no \nNo response to typical management treatment \no \nCluster headache  \n\u00b7 \nValproate sodium, and/or Magnesium sulfate, and/or consider \nother adjunctive options, if not already given (See Appendix)\nUNSUCCESSFUL \n\u00b7 \nConsider occipital nerve block if occipital tenderness is present\n\u00b7 \nEliminate secondary causes (see page 2)\nUNSUCCESSFUL \nUNSUCCESSFUL \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, \nmodified, or distributed in any form without a written agreement with The Ohio State University Technology \nCommercialization Office (https://tco.osu.edu/)\nUNSUCCESSFUL \nInpatient Admission\n\u00a7 \nArrange for Primary Care follow-up\n\u00a7 \nConsider Neurology follow-up (see \npage 2)\n\u00a7 \nConsider providing antiemetic \nprescription \nOSUWMC Clinical Practice Guideline\n[Month Approved] 2022\nTreatment of Acute Non-Life-Threatening Headache:\nED and Inpatient\nWhat You Need to Know\n\u00b7 \nHydration is a first line treatment for symptom relief\n\u00b7 \nConsider Neurology consult in patients with life-threatening etiologies, \nfrequent ED visits or no response to typical therapies\n\u00b7 \nOpioids are NOT recommended for symptom relief\n\u00b7 \nConsider IV dexamethasone to prevent ED readmission\nConsider Head CT to R/O mass or bleed\nAdmit and Consult Neurology \nRefer to appropriate guideline based on \nresult of CT and location of bleed\n(Intracerebral Hemorrhage or \nSubarachnoid Hemorrhage)\nAdmit and Consult Neurology \nRefer to appropriate guideline based on \nresult of CT and location of bleed\n(Intracerebral Hemorrhage or \nSubarachnoid Hemorrhage)\nScreen for symptoms or conditions that suggest a \npotential life-threatening headache etiology\nInitial Treatment\nSee page 2\nSUCCESSFUL\nNO\nHead CT Result?\nPOSITIVE\nNEGATIVE\nPotential Life-Threatening Headache?\nYES\u00b7 New seizure, abnormal neurologic  or vision exam that includes third nerve palsy, unilateral pupil dilation, and/or ptosis (eyelid drooping)\u00b7 Altered mental status\u00b7 Concern for subarachnoid hemorrhage (severe-rapid onset headache \u2013 \u201cthunderclap headacheatypical or intractable headache)o Arrival by ambulance o Syncope at the onset of headacheo History of recent significant head trauma\u00b7 Concern for meningitis (fever, meningismus, etc.)\u00b7 Concern for temporal arteritis (scalp tenderness to palpation, jaw claudication)\u00b7 Comorbid conditions that place patient at higher risk for life-threatening headache etiologies (HIV+, malignancy, pregnant, < 4 weeks postpartum) see OSUWMC  Management of Severe Hypertension \nf\nor the Obstetrical Patient Guideline\n\u00b7 \nJudgment of treating physician\n", "2 \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any \nform without a written agreement with The Ohio State University Technology Commercialization Office (https://tco.osu.edu/) \nInitial Treatment \n\u2022\nIV hydration as tolerated\n\u2022\nPharmacological management - consider the following (see Appendix):\no\nOral analgesics (non-narcotic)\no\n5-HT if success in the past with 5-HT, headache onset < 4 hours, or presumed to be migraine (see Appendix for \ncontraindications)\no\nIV Prochlorperazine (Compazine\u00ae) or IV Haloperidol (Haldol\u00ae) plus IV Diphenhydramine (Benadryl\u00ae) or IV \nBenztropine (Cogentin\u00ae)\no\nIV/IM Ketorolac (Toradol\u00ae)\n\uf0a7\nContraindicated if hemorrhage suspected, and/or cardiovascular or renal disease\no\nDexamethasone 10 mg IV/IM (to prevent recurrence for migraines only)\no\nTriptans if success in the past with Triptans, headache onset < 4 hours, or presumed to be migraine (see \nAppendix for contraindications)\n\u2022\nNote: Opiates are strongly discouraged due to the risk of dependence and resulting increased risk of rebound \nheadache; however, consider opiates if patient has contraindications to other pharmacologic management options, or \nas rescue medication.\nAmbulatory Neurology Referral for Headaches \nNote: It is important to establish a correct diagnosis of recurrent headaches including tension, migraine, and \ncluster.  Moreover, it is important to establish a correct diagnosis of other head pain syndromes such as trigeminal \nneuralgia. \nThe following criteria can be used when making a diagnosis and determining the need for outpatient neurology referral: \n\u2022\nAbnormal neurologic examination:\no\nConsider imaging studies: non-contrast brain MRI, preferred\n\u2022\nNew onset headaches and age > 50 years\no\nConsider imaging\no\nEvaluate for temporal arteritis\n\u2022\nPatients with prior headache history and/or:\no\nNo or poor response to appropriate trial of symptomatic therapy\n\uf0a7\nNSAIDs\n\uf0a7\n> 2 Triptans\no\nChronic daily headache\n\uf0a7\n> 15 headache days per month with or without medication overuse\no\nSignificant psychiatric comorbidity such as:\n\uf0a7\nDepression\n\uf0a7\nAnxiety\n\uf0a7\nEpilepsy\no\nIncreased frequency and disability of headaches along with failed adequate trial of at least one standard preventive\nmedication:\n\uf0a7\nTopiramate\n\uf0a7\nTri-cyclic antidepressant\n\uf0a7\nBeta-blocker\n\uf0a7\nValproate\n\u2022\nPrior migraine with aura history and frequent/prolonged aura, complicated or possible hemiplegic migraine\nSecondary Causes of Acute Headaches \n\u2022\nHydrocephalus\n\u2022\nEncephalitis\n\u2022\nAcute Angel closure glaucoma\n\u2022\nAcute sinusitis\n\u2022\nSystemic infection\n\u2022\nMedication-induced headache\n", "3 \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any \nform without a written agreement with The Ohio State University Technology Commercialization Office (https://tco.osu.edu/) \nOSUWMC Resources \nOrder Sets \n\u2022\nED: CDU/OBS HEADACHE [2367]\n\u2022\nED: HEADACHE [2517]\nGuidelines \n\u2022\nManagement of Severe Hypertension for the Obstetrical\nPatient\nReferences \n\u2022\nEdlow JA, et al. (2008). Clinical Policy: Critical Issues in\nthe Evaluation and Management of Adult Patients\nPresenting to the Emergency Department with Acute\nHeadache. Annals of Emergency Medicine, 52:407-434.\n\u2022\nFriedman BW, et al. (2008). A Randomized Control Trial\nof Prochlorperazine versus Metoclopramide for\nTreatment of Acute Migraine. Annals of Emergency\nMedicine, 52:399-406.\n\u2022\nFriedman BW and Lipton RB. (2011). Headache in the\nEmergency Department. Current Pain and Headache\nReports. DOI 10.1007/s11916-011- 0189-z\n\u2022\nGilmore B, Michael M. (2011). Treatment of acute\nmigraine headache. American Family Physician,\n83(3):271-80.\n\u2022\nLevin, M. (2015, December). Approach to the workup\nand management of headache in the emergency\ndepartment and inpatient settings. In Seminars in\nneurology (Vol. 35, No. 06, pp. 667-674). Thieme Medical\nPublishers.\n\u2022\nMatchar DB, et al. (2000). Evidence-Based Guidelines for\nMigraine Headache in the Primary Care Setting:\nPharmacological Management of Acute Attacks.\nAmerican Headache Society.\n\u2022\nMatthew NT. (2009) Treatment of Headache. Textbook of\nStereotactic and Functional Neurosurgery, 2483-2505.\n\u2022\nMinen, M. (2014). Evaluation and Treatment of migraine\nin the Emergency Department: A Review. Headache, 54:\n1131-1145.\n\u2022\nOrr, Serena L., et al. \"Management of adults with acute\nmigraine in the emergency department: the American\nHeadache Society evidence assessment of parenteral\npharmacotherapies.\" Headache: The Journal of Head and\nFace Pain 56.6 (2016): 911-940.\n\u2022\nRobertson CE, et al. (2010). Management of Migraine\nHeadache in the Emergency Department. Seminars in\nNeurology, 30(2):201- 11.\n\u2022\nTang, Yongguo, et al. \"Influence of greater occipital nerve\nblock on pain severity in migraine patients: A systematic\nreview and meta-analysis.\" The American journal of\nemergency medicine 35.11 (2017): 1750-1754.\n\u2022\nWu, Shuzhi, et al. \"The efficacy of greater occipital nerve\nblock for the treatment of migraine: A systematic review\nand meta-analysis.\" Clinical neurology and neurosurgery\n(2018).\nGuideline Authors \n\u2022\nColin Kaide, MD\n\u2022\nElena Petrovski\n\u2022\nAnn Pakalnis, MD\n\u2022\nErin Reichert, PharmD\n\u2022\nKristi Epstein, APRN-CNP\n\u2022\nKevin Weber, MD\nPrevious Author (inpatient) \n\u2022\nDaniel Shenoi, MD\nGuideline reviewed by: Hospital Medicine Quality Committee \nQuality Measures \n\u2022\nED\no\nPercent of patients who received IV hydration\no\nPercent of patients who returned to ED within 3 days\no\nPercent of patients who had two outpatient visits to\nED, or one inpatient admission per month\n\u2022\nInpatient\no\nPercent of inpatients who received head CT for new\nonset severe headache\no\nPercent of inpatients who received a Neurology\nconsult for headache\no\nPercent of inpatients who received occipital nerve\nblock for headache\nGuideline Approved \nDisclaimer: Clinical practice guidelines and algorithms at The \nOhio State University Wexner Medical Center (OSUWMC) are \nstandards that are intended to provide general guidance to \nclinicians. Patient choice and clinician judgment must remain \ncentral to the selection of diagnostic tests and therapy. \nOSUWMC\u2019s guidelines and algorithms are reviewed \nperiodically for consistency with new evidence; however, new \ndevelopments may not be represented.\nJuly 27, 2022.  Fifth Edition\n", "4 \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio \nState University Technology Commercialization Office (https://tco.osu.edu/) \nAPPENDIX: Acute Headache Medications \nDrug \nDose \nRe-Dose \nSide Effects \nContraindications \nKetorolac \n(Toradol\u00ae) \n15 \u2013 30 mg IVP or \n15 - 60 mg IM \n \nFor elderly patients and/\nor < 50 kg, give 15 mg* \n\u2022 May repeat in 6 hours \n\u2022 Do not exceed 120 mg in \n24 hours \n\u2022\nNausea\n\u2022 Epigastric\npain \n\u2022\nDyspepsia\n\u2022\nDizziness\n\u2022\nRash\n\u2022\nTinnitus\n\u2022\nEdema, fluid\nretention\n\u2022\nAcute renal failure\n\u2022\nActive peptic ulcer disease\n\u2022\nRenal insufficiency\n\u2022\nActive bleeding\n\u2022\nKnown hypersensitivity to NSAIDs\n\u2022\nCardiovascular disease\nDexamethasone \n(Decadron\u00ae) \n10 mg IM or IVP over 3-5 \nminutes \nUse cautiously in the elderly \nat the lowest possible dose \n(e.g., < 5 mg)* \n\u2022\nFluid and electrolyte disturbances\n(hypokalemia)\n\u2022\nMuscle weakness\n\u2022\nPeptic ulcer\n\u2022\nBurning or tingling in the perineal\narea after IV administration \n\u2022\nImpaired wound healing\n\u2022\nConvulsions\n\u2022\nPsychiatric disturbances\n\u2022\nHyperglycemia\n\u2022\nIncreased intraocular pressure\n\u2022\nHypersensitivity reactions\nDihydroergotamine \n(D.H.E. 45\u00ae) \n1 mg SQ, IM, or IVP over \n1 \u2013 3 minutes or 1 mg IVPB \nover 30 minutes \n\u2022\nMay repeat in 8 hours\n\u2022\nDo not exceed 3 mg in\n24 hours \n\u2022\nCoronary artery vasospasm\n\u2022\nTransient myocardial ischemia\n\u2022\nVentricular tachycardia and\nventricular fibrillation\n\u2022\nTachycardia\n\u2022\nCoronary vasoconstriction\n\u2022\nLeg cramps\n\u2022\nNausea/vomiting\n\u2022\nParesthesia\n\u2022\nMiosis\n\u2022\nShould be avoided in older adults\n\u2022\nIschemic heart disease (angina,\nhistory of myocardial infarction)\n\u2022\nPeripheral vascular disease\n\u2022\nUncontrolled hypertension\n\u2022\nPregnancy\n\u2022\nConcurrent use of 5-HT1 agonists\nwithin 24 hours\n\u2022\nPatients with hemiplegic or basilar\nmigraine\no\nBasilar migraines are defined by\nthree of the following features:\ndiplopia, dysarthria, tinnitus,\nvertigo, transient hearing loss, or\nmental confusion\n\u2022\nSevere hepatic or renal dysfunction\n\u2022\nKnown hypersensitivity to ergot\nalkaloids\n\u2022\nFollowing vascular surgery\n\u2022\nSepsis or hypotension\n*Older adult dosing adjustment or avoidance is appropriate. Please review specific guidance by line item for each medication.\n", "5 \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio \nState University Technology Commercialization Office (https://tco.osu.edu/) \nDrug \nDose \nRe-Dose \nSide Effects \nContraindications \n(Inaspine\u00ae) \nover 2 \u2013 5 minutes \n\u2022 \nMay repeat in 2 hours \n\u2022 Drowsiness\nDroperidol \n0.625 - 2.5 mg IM or IVP \n\u2022 Extrapyram\n \nidal reactions\n\u2022\nHypotension\n\u2022\nCaution in patients taking concurrent\nQT prolonging medications\n\u2022\nSignificant cardiovascular history\n\u2022\nElectrolyte abnormalities\nCaffeine \n200 mg PO \n\u2022\nMay repeat in 2-3 \nhours \n\u2022 Tachycardia\n\u2022 Cardiac arrhythmias\n\u2022\nAnxiety\nHaloperidol \n(Haldol\u00ae) \n1.25 \u2013 2.5 mg IM or IVP \nover 3 \u2013 5 minutes \nFor elderly patients, initiate \nat lower dosage (e.g., 0.25 \nmg) over 3-5 minutes* \n\u2022 \nMay repeat in 2 hours\n \n\u2022\nDo not exceed 1 mg in\n15 minutes; May \nrepeat, but do not \nexceed 2 mg in 24 \nhours for older adults* \n\u2022\nExtrapyramidal reactions\no consider administering with\ndiphenhydramine or benztropine\n\u2022\nDrowsiness\n\u2022\nHypotension, hypertension\n\u2022\nBlurred vision\n\u2022\nCaution in patients taking concurrent\nQT prolonging medications\n\u2022\nSignificant cardiovascular history\n\u2022\nElectrolyte abnormalities\nMagnesium Sulfate \nminutes \n\u2022 \nMay repeat in 2 hours \n\u2022\nFlushing, sweating\n\u2022\n1 gram IVPB over 10   \n\u2022 \n \nHypotension\nDepressed reflexes\n\u2022\nFlaccid paralysis\n\u2022\nCirculatory collapse\n\u2022\nCaution in renal insufficiency\nMetoclopramide \n(Reglan\u00ae) \n10 mg IM or IVP over \n1 \u2013 2 minutes \nFor elderly patients, initiate \nat lower end of dosage \nrange, (e.g., 5 mg) and \nincrease dose slowly and \ncautiously* \n\u2022\nMay repeat in 4 hours\n\u2022\nExtrapyramidal reactions (give with\ndiphenhydramine or benztropine)\n\u2022\nDrowsiness, fatigue\n\u2022\nInsomnia\n\u2022\nGalactorrhea, amenorrhea\n\u2022\nHypotension, hypertension\n\u2022\nSupraventricular tachycardia,\nbradycardia\n\u2022\nNausea, diarrhea\n\u2022\nUrinary frequency, incontinence\n\u2022\nPheochromocytoma\n\u2022\nEpilepsy\nProchlorperazine \n(Compazine\u00ae) \n10 mg IM or IVP over 2 min. \nFor elderly patients, initiate \nat lower end of dosage \nrange, (e.g., 5 mg) and \nincrease dose slowly and \ncautiously* \n\u2022\nMay repeat in 4 hours\n\u2022\nDo not exceed 40 mg\nin 24 hours\n\u2022\nExtrapyramidal reactions (give with\ndiphenhydramine or benztropine)\n\u2022\nDrowsiness, dizziness, blurred vision\n\u2022\nAmenorrhea\n\u2022\nHypotension\n\u2022\nKnown allergy to phenothiazines\n*Older adult dosing adjustment or avoidance is appropriate. Please review specific guidance by line item for each medication.\n", "6 \nCopyright \u00a9 2011. The Ohio State University. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio \nState University Technology Commercialization Office (https://tco.osu.edu/) \nDrug \nDose \nRe-Dose \nSide Effects \nContraindications \nSumatriptan \n(Imitrex\u00ae) \n25 - 100 mg PO \n\u2022\nMay repeat in 2 hours\n\u2022\nDo not exceed 200 mg\nin 24 hours\n\u2022\nChest tightness or pressure\n\u2022\nParesthesia\n\u2022\nJaw tightness or pressure\n\u2022\nDizziness\n\u2022\nNausea\n\u2022\nMyalgia\n\u2022\nUncontrolled hypertension\n\u2022\nHistory of ischemic heart disease\n(myocardial infarction, angina)\n\u2022\nHistory of peripheral vascular disease\n\u2022\nHistory of cerebrovascular disease\n(ischemic and hemorrhagic)\n\u2022\nConcurrent use of monoamine\noxidase (MAO) inhibitors\n\u2022\nSevere hepatic impairment\n\u2022\nConcurrent use with ergotamine\ncontaining or ergot type medication\n\u2022\nHypersensitivity to sumatriptan\n\u2022\nUse of dihydroergotamine within 24\nhours\n6 mg SQ \n\u2022\nMay repeat in 2 hours\n\u2022\nDo not exceed 12 mg\nin 24 hours\nValproate Sodium \n(Depacon\u00ae) \n500 mg IVPB over 15 min. \nFor elderly patients, lower \ninitial doses (e.g., 125 mg) \nare recommended due to \ndecreased elimination and \nincreased incidences* \n\u2022\nMay repeat in 6 hours\n\u2022\nDo not exceed 2,000 \nmg in 24 hours \n\u2022\nRash\n\u2022 Dizziness\n\u2022 Nystagmus\n\u2022\nSomnolence\n\u2022\nTremor\n\u2022\nDiplopia\n\u2022\nPregnancy\n\u2022\nSevere hepatic dysfunction\n\u2022\nKnown hypersensitivity to valproate\nsodium\n*Older adult dosing adjustment or avoidance is appropriate. Please review specific guidance by line item for each medication.\n"], "metadatas": [{"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738113", "filename": "AcuteHeadache 1.pdf"}, {"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738133", "filename": "AcuteHeadache 1.pdf"}, {"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738136", "filename": "AcuteHeadache 1.pdf"}, {"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738139", "filename": "AcuteHeadache 1.pdf"}, {"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738141", "filename": "AcuteHeadache 1.pdf"}, {"source": "predefined-pdfs/AcuteHeadache 1.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:29:12.738144", "filename": "AcuteHeadache 1.pdf"}]}